Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study).
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fernández Ignacio Peláez, Lorenzo Verónica Blanco, Dominguez Rocío García, Gómez Clara Iglesias, Molina-Cerrillo Javier, Carbonero Icíar García, Feliciangeli Eduardo, Ruiz Saray Galván, de Liaño Alfonso Gómez, Valderrama Begoña Pérez, Sánchez Ángel Rodríguez, Morcuende Ricardo Sánchez-Escribano, Rodríguez Cristina Suárez, Quintela Martín Emilio Lázaro, Díaz Enrique Gallardo, Padró Josep Gumà I, Puente Javier, Guzman José Carlos Villa, Sanchez José García, Kareaga Mireia Martínez, Zambrana María Del Carmen Beato, de Velasco Guillermo, Cabrero Isabel Ruiz, García-Donas Jesús, Munarriz Javier, Sarrió Regina Gironés, Núñez Natalia Fernández, Gordoa Teresa Alonso, Esteban Emilio
Аннотация
METHODS/PATIENTS: This retrospective multicenter study included patients from 25 centers treated with antiangiogenic therapy without prior exposure to immune checkpoint inhibitors. Clinical and pathological data were obtained from medical records, and PD-L1 expression was centrally assessed in primary tumor samples using the 22C3 pharmDx assay. Survival was analyzed using Kaplan-Meier estimates, log-rank tests, and Cox regression models. Tumor samples were also analyzed by next-generation sequencing using a customized panel.
RESULTS: Of 340 identified patients, 242 (71.2%) were evaluable. The median age was 64 years, and 76.4% were men. International Metastatic RCC Database Consortium risk was favorable in 7.8%, intermediate in 55.4%, and poor in 36.7%. First-line therapy consisted mainly of sunitinib (70.7%) or pazopanib (26.0%). PD-L1 expression was <1% in 84.7% and ≥1% in 15.3% of tumors. Median overall survival was 14.5 months for PD-L1 <1% and 9.7 months for PD-L1 ≥1% (p = 0.0023). In multivariable analysis, PD-L1 ≥1%, poor risk, and >1 metastatic site were independently associated with worse overall survival.
CONCLUSIONS: PD-L1 expression ≥1% is an independent adverse prognostic factor in mRCC treated with antiangiogenic therapy and may help refine prognostic stratification and treatment planning.